Search Tufts Medicine

This study is being conducted in patients with refractory Mycobacterium Avium Complex (MAC), a serious condition which can cause damage to your lung, and is resistant to other treatments. The study is looking at how effective the study drug, Epetraborole in the treatment of refractory MAC. Epetrabole is a oral pill to be taken as 2 tablets one time daily by mouth. Details of study visits are explained below.

This trial will help to determine if either the experimental arm (adjuvant reirradiation plus pembrolizumab, followed by pembrolizumab to complete 12 months total of pembrolizumab and/or pembrolizumab alone for 12 months) significantly improves Overall Survival (OS) compared to adjuvant reirradiation plus concurrent platinum chemotherapy in high risk patients.

Recent studies have shown that the causative agent of Lyme disease, the organism (Borrelia burgdorferi), may persist in animals after antibiotic treatment and can be detected by using natural tick vector (Ixodes scapularis) to acquire the organism through feeding (xenodiagnosis). The aim of this study is to investigate the utility of xenodiagnosis for identifying persistence of infection with B. burgdorferi in treated human Lyme disease.

This is a randomized, open-label study of HLX10 plus chemotherapy (Carboplatin-Etoposide) in comparison with Atezolizumab plus chemotherapy in previously untreated US patients with ES-SCLC. Subjects in this study will be randomized to arm A or B at 1:1 ratio as follows: Arm A (HLX10): HLX10 + chemotherapy (carboplatin-etoposide) Arm B (control): Atezolizumab + chemotherapy (carboplatin-etoposide)

This is a Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase 2b Study, with the objective of comparing Progression-Free Survival (PFS) in newly diagnosed GBM patients treated with IGV-001 with patients treated with placebo.

The study will evaluate the efficacy, safety and pharmacokinetics of faricimab compared with aflibercept in patients with macular edema due to branch retinal vein occlusion (BRVO) up to the primary endpoint at Week 24.

Our main goal is to use a special type of microscopic imaging to help detect cervical pre-cancers without the need for labels or dyes. We've been working closely with doctors at Tufts Medical Center for more than ten years and have studied images from over seventy cervical tissue samples taken from humans. We shine a laser on the tissues with two different types of light, and this caused certain molecules in the cells to give off light, which we collected and analyzed. By scanning the tissues in this way, we could make 3D images and measure how the cell structures changed with depth.

The proposed study compares Tai Chi + Routine Care with Routine Care alone to see if the addition of Tai Chi to Routine Care can improve Knee OA pain. The study will be conducted at Tufts Medical Center, UCLA, Boston Medical Center, and Cleveland Clinic. The study is funded by the National Institutes of Health National Center for Complementary and Integrative Health. We expect to enroll up to 480 subjects across all sites needed to complete the study

The purpose of this study is to evaluate the efficacy and safety of selinexor as a maintenance treatment in patients with p53 wt endometrial carcinoma, who have achieved a partial response or complete response after completing at least 12 weeks of platinum-based therapy.

This phase II trial studies how well radiation therapy with or without cisplatin works in treating patients with stage III-IVA squamous cell carcinoma of the head and neck who have undergone surgery.

Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

A prospective, multi-center, 2:1 randomized (AGENT to POBA), controlled, single-blind, superiority trial. Up to 40 sites in the United States, at least 480 subjects will be enrolled in the trial. An interim analysis will be performed prior to the end of the initial enrollment of 480 patients. The final sample size may be increased up to a maximum of 600 subjects enrolled in the trial.

The primary goal of this study is to improve our understanding of changes in skeletal muscle mass in the arms and the legs during a hospitalization for advanced HF. We plan to measure muscle thickness with an ultrasound machine in two locations on the body (the outer thigh and the upper arm muscle, of the dominant side) from the time a patient is first admitted to the ICU with HF as well as before and after any surgical HF therapies.